Cargando…

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval

BACKGROUND: Regulatory approval of novel therapies by the FDA does not guarantee insurance coverage requisite for most clinical use. In the United States, the largest health insurance payer is the Centers for Medicare & Medicaid Services (CMS), which provides Part D prescription drug benefits to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaw, Daniel L., Dhruva, Sanket S., Ross, Joseph S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397592/ https://www.ncbi.nlm.nih.gov/pubmed/30479199 http://dx.doi.org/10.18553/jmcp.2018.24.12.1230

Ejemplares similares

Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study
por: Roginiel, Aliya C., et al.
Publicado: (2018)

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
por: Rathi, Vinay K, et al.
Publicado: (2023)

Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
por: Bartlett, Victoria L., et al.
Publicado: (2020)

Changing FDA Approval Standards: Ethical Implications for Patient Consent
por: Darrow, Jonathan J., et al.
Publicado: (2021)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Prescription Drug Coverage and Spending for Medicare Beneficiaries
por: Poisal, John A., et al.
Publicado: (1999)

MCBS Highlights: Prescription Drug Coverage Among Medicare Beneficiaries
por: Regan, Joseph F., et al.
Publicado: (2007)

The impact of Medicare prescription drug coverage on the use of antidementia drugs
por: Fowler, Nicole R, et al.
Publicado: (2013)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
por: Wallach, Joshua D., et al.
Publicado: (2021)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans
por: Newman, Terri Victoria, et al.
Publicado: (2022)

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
por: Mooghali, Maryam, et al.
Publicado: (2023)

Medicare Quality Improvement Organizations' Ambulatory Drug Therapy Improvement Activities and Partnerships With Medicare Part D Prescription Drug Plans and Medicare Advantage Plans
por: Schulke, David G., et al.
Publicado: (2007)

Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014)

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
por: Brockmann, Rouen, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
por: Mellini, Marta, et al.
Publicado: (2019)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Diagnosis-Based Risk Adjustment for Medicare Prescription Drug Plan Payments
por: Robst, John, et al.
Publicado: (2007)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
por: Pease, Alison M, et al.
Publicado: (2017)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Psychometric Properties of an Instrument to Assess Medicare Beneficiaries' Prescription Drug Plan Experiences
por: Martino, Steven C., et al.
Publicado: (2009)

Patient Experiences in Selecting a Medicare Part D Prescription Drug Plan
por: Stults, Cheryl D, et al.
Publicado: (2017)

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
por: Li, Mei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tcodc7kt3mngkqn3ccneuhkgs3